ArticleBriefings in bioinformatics2026
Multi-marker testing based on accelerated failure time models under possible left truncation and competing risks.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Kernel-based multi-marker tests for survival outcomes use primarily the Cox model to adjust for covariates. The proportional hazards assumption made by the Cox model could be unrealistic, especially in the long-term follow-up. We develop a suite of novel multi-marker survival tests for genetic association and interaction based on the accelerated failure time model, which is a popular alternative to the Cox model due to its direct physical interpretation. The tests are based on the asymptotic distributions of their test statistics and are thus computationally efficient. The association tests can account for the heterogeneity of genetic effects across subpopulations/individuals to increase the power. All the new tests can deal with competing risks and left truncation. Moreover, we develop small-sample corrections to the tests to improve their accuracy under small samples. Extensive numerical experiments show that the new tests perform very well in various scenarios. An application to a genetic dataset of Alzheimer's disease illustrates the tests' practical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.